Head & Neck Cancers | Clinical

Only Numerical Improvement in Survival Seen in Locally Advanced HNSCC With Pembrolizumab Plus Chemoradiation

September 11, 2022

Patients with locally advanced head and neck squamous cell carcinoma did not show statistically significant improvement in event-free survival with pembrolizumab plus chemoradiation vs chemoradiation alone.

Xevinapant Plus CRT in Locally Advanced HNSCC Shows Continued Benefit

September 11, 2022

Improvement in overall survival for patients with locally advanced head and neck squamous cell carcinoma was demonstrated with xevinapant plus standard chemoradiotherapy vs matched placebo at the 5-year mark.

ERASCA and Eli Lilly Collaborate to Investigate ERAS-601 and Cetuximab Combination

August 05, 2022

Erasca has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company to evaluate the anti-EGFR antibody cetuximab.

Study of Monalizumab and Cetuximab in Recurrent/Metastatic SCCHN Discontinued

August 01, 2022

The phase 3 INTERLINK-1 study of monalizumab and cetuximab as treatment of recurrent or metastatic squamous cell carcinoma of the head and neck has been discontinued. The study did not meet its efficacy goal.

Phase 2 INSPIRE Trial of IRX-2 Misses EFS End Point in Head and Neck Cancer

July 28, 2022

IRX-2 did not demonstrate a statistically significant improvement in event-free survival as neoadjuvant therapy vs standard of care in patients with newly diagnosed, stage II, III, or IVA squamous cell carcinoma of the oral cavity, according to data from the phase 2 INSPIRE trial.

KEYNOTE-412 Fails to Show EFS Advantage in Unresected Locally Advanced HNSCC

July 20, 2022

Patients with unresected locally advanced head and neck squamous cell carcinoma did not show a significant improvement in event-free survival when treated with pembrolizumab and concurrent chemoradiation followed by pembrolizumab maintenance in the phase 3 KEYNOTE-412 study.

HPV-Related Late-Stage Throat Cancer Rises in Males and Displays Racial Disparities

July 12, 2022

Hispanic and Black men are showing higher cancer-specific mortality rates from HPV-associated throat cancer, and most new cases are being diagnosed in White men at a late-stage.

FDA Accepts BLA Resubmission for Toripalimab in Advanced Nasopharyngeal Carcinoma

July 07, 2022

A biologics license application resubmission for toripalimab in combination with gemcitabine and cisplatin and for toripalimab monotherapy has been accepted by the FDA.

Frontline Tislelizumab Plus Chemo Improves PFS in Recurrent/Metastatic Nasopharyngeal Cancer

June 09, 2022

Benefit across a range of survival end points, including progression-free survival, shown with tislelizumab and chemotherapy for patients with recurrent or metastatic nasopharyngeal carcinoma.

HPV16+ HNSCC Response to PDS0101 Plus Pembrolizumab in VERSATILE-002

June 08, 2022

In CPI-naïve, HPV16-positive, CPS-positive patients, PDS0101 plus pembrolizumab exhibits preliminary evidence of clinical benefit in a majority of patients with an acceptable safety profile and allows continued dosing of pembrolizumab.